Evidence map›Paper›PMID 35407605›Full record

ArticleJournal of clinical medicine2022

New Analytical Approach for the Alignment of Different HE4 Automated Immunometric Systems: An Italian Multicentric Study.

Antonio Angeloni, Corrado De Vito, Antonella Farina, Daniela Terracciano, Michele Cennamo, Rita Passerini, Fabio Bottari, Annalisa Schirinzi, Roberto Vettori, Agostino Steffan and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis.International journal of molecular sciences · 2023
    Review
  6. Ovarian Cancer Biomarkers in the COVID-19 Era.International journal of environmental research and public health · 2023
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Antonio AngeloniDepartment of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
Corrado De VitoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Antonella FarinaDepartment of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.ORCID 0000-0002-8629-0971
Daniela TerraccianoDepartment of Translation Medical Sciences, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0003-4296-429X
Michele CennamoDepartment of Translation Medical Sciences, University of Naples Federico II, 80131 Naples, Italy.
Rita PasseriniDivision of Laboratory Medicine, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Fabio BottariDivision of Laboratory Medicine, European Institute of Oncology, IRCCS, 20141 Milan, Italy.ORCID 0000-0003-1838-0163
Annalisa SchirinziClinic Pathology Unit, University Hospital, Policlinico di Bari, 70124 Bari, Italy.
Roberto VettoriImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO Aviano), IRCCS, National Cancer Institute, 33081 Aviano, Italy.
Agostino SteffanImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO Aviano), IRCCS, National Cancer Institute, 33081 Aviano, Italy.ORCID 0000-0002-6320-3054
Valerio MaisDepartment of Surgical Sciences, University of Cagliari Medical School, 09042 Cagliari, Italy.ORCID 0000-0002-1362-9102
Ferdinando CogheDepartment of Laboratory Medicine, University Hospital, 09123 Cagliari, Italy.
Luigi Della CorteDepartment of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, 80131 Naples, Italy.
Giuseppe BifulcoDepartment of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, 80131 Naples, Italy.
Valentina BaccoliniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-7873-7817
Elena BerardelliDepartment of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
Giuseppe MigliaraDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-4573-6025
Emanuela AnastasiDepartment of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.ORCID 0000-0002-5124-3219
Sapienza University of Rome · ITUniversity of Naples Federico II · ITCentro di Riferimento Oncologico · ITEuropean Institute of Oncology · ITUniversity of Cagliari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epididymal secretory protein 4 (HE4) elevation has been studied as a crucial biomarker for malignant gynecological cancer, such us ovarian cancer (OC). However, there are conflicting reports regarding the optimal HE4 cut-off. Thus, the goal of this study was to develop an analytical approach to harmonize HE4 values obtained with different laboratory resources. To this regard, six highly qualified Italian laboratories, using different analytical platforms (Abbott Alinity I, Fujirebio Lumipulse G1200 and G600, Roche Cobas 601 and Abbott Architett), have joined this project. In the first step of our study, a common reference calibration curve (designed through progressive HE4 dilutions) was tested by all members attending the workshop. This first evaluation underlined the presence of analytical bias in different devices. Next, following bias correction, we started to analyze biomarkers values collected in a common database (1509 patients). A two-sided p-value < 0.05 was considered statistically significant. In post-menopausal women stratified between those with malignant gynecological diseases vs. non-malignant gynecological diseases and healthy women, dichotomous HE4 showed a significantly better accuracy than dichotomous Ca125 (AUC 0.81 vs. 0.74, p = 0.001 for age ≤ 60; AUC 0.78 vs. 0.72, p = 0.024 for age > 60). Still, in post-menopausal status, similar results were confirmed in patients with malignant gynecological diseases vs. patients with benign gynecological diseases, both under and over 60 years (AUC 0.79 vs. 0.73, p = 0.006; AUC 0.76 vs. 0.71, p = 0.036, respectively). Interestingly, in pre-menopausal status women over 40 years, HE4 showed a higher accuracy than Ca125 (AUC 0.73 vs. 0.66, p = 0.027), thus opening new perspective for the clinical management of fertile patients with malignant neoplasms, such as ovarian cancer. In summary, this model hinted at a new approach for identifying the optimal cut-off to align data detected with different HE4 diagnostic tools.

Indexed as

biomarkershuman epididymal secretory protein 4 (HE4)multicentric studyovarian cancer

Identifiers

PMID35407605
PMCPMC9000204
OpenAlexW4223533559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.